{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:39:35Z","timestamp":1792629575715,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"vor","delay-in-days":87,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["no. 82570148"],"award-info":[{"award-number":["no. 82570148"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the 1\u22193\u22195 Project of State Key Laboratory of Respiratory Health and Multimorbidity, West China Hospital, Sichuan University","award":["RHM24206"],"award-info":[{"award-number":["RHM24206"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16618-7","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T06:35:44Z","timestamp":1785134144000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical and pathological characteristics, immune microenvironment, and survival analysis of molecular subtypes of surgically resected small cell lung cancer"],"prefix":"10.1186","volume":"26","author":[{"given":"Juncai","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huohuan","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuewen","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"16618_CR1","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.semcancer.2022.05.010","volume":"86","author":"J Liang","year":"2022","unstructured":"Liang J, Guan X, Bao G, et al. Molecular subtyping of small cell lung cancer. Semin Cancer Biol. 2022;86:450\u201362.","journal-title":"Semin Cancer Biol"},{"key":"16618_CR2","doi-asserted-by":"publisher","first-page":"108033","DOI":"10.1016\/j.lungcan.2024.108033","volume":"198","author":"Z Yu","year":"2024","unstructured":"Yu Z, Zou J, Xu F. The molecular subtypes of small cell lung cancer defined by key transcription factors and their clinical significance. Lung Cancer. 2024;198:108033.","journal-title":"Lung Cancer"},{"issue":"3","key":"16618_CR3","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.ccell.2020.12.014","volume":"39","author":"CM Gay","year":"2021","unstructured":"Gay CM, Stewart CA, Park EM, et al. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell. 2021;39(3):346\u2013. \u2013\u200960.e7.","journal-title":"Cancer Cell"},{"issue":"Pt 2","key":"16618_CR4","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.semcancer.2022.05.005","volume":"86","author":"J Kashima","year":"2022","unstructured":"Kashima J, Okuma Y. Advances in biology and novel treatments of SCLC: The four-color problem in uncharted territory. Semin Cancer Biol. 2022;86(Pt 2):386\u201395.","journal-title":"Semin Cancer Biol"},{"issue":"14","key":"16618_CR5","doi-asserted-by":"publisher","first-page":"3568","DOI":"10.3390\/cancers15143568","volume":"15","author":"J Kim","year":"2023","unstructured":"Kim J, Kim S, Park SY, et al. Molecular Subtypes and Tumor Microenvironment Characteristics of Small-Cell Lung Cancer Associated with Platinum-Resistance. Cancers (Basel). 2023;15(14):3568.","journal-title":"Cancers (Basel)"},{"key":"16618_CR6","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.omto.2021.02.004","volume":"20","author":"A Schwendenwein","year":"2021","unstructured":"Schwendenwein A, Megyesfalvi Z, Barany N, et al. Molecular profiles of small cell lung cancer subtypes: Therapeutic implications. Mol Ther\u2013Oncolytics. 2021;20:470\u201383.","journal-title":"Mol Ther\u2013Oncolytics"},{"issue":"5","key":"16618_CR7","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41568-019-0133-9","volume":"19","author":"CM Rudin","year":"2019","unstructured":"Rudin CM, Poirier JT, Byers LA, et al. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nat Rev Cancer. 2019;19(5):289\u201397.","journal-title":"Nat Rev Cancer"},{"key":"16618_CR8","doi-asserted-by":"publisher","first-page":"741","DOI":"10.3389\/fonc.2020.00741","volume":"10","author":"H Taniguchi","year":"2020","unstructured":"Taniguchi H, Sen T, Rudin CM. Targeted Therapies and Biomarkers in Small Cell Lung Cancer. Front Oncol. 2020;10:741.","journal-title":"Front Oncol"},{"issue":"1","key":"16618_CR9","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1136\/jcp-2023-209109","volume":"78","author":"Y Zhu","year":"2023","unstructured":"Zhu Y, Li S, Wang H, et al. Molecular subtypes, predictive markers and prognosis in small-cell lung carcinoma. J Clin Pathol. 2023;78(1):42\u201350.","journal-title":"J Clin Pathol"},{"issue":"1","key":"16618_CR10","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41698-025-00860-6","volume":"9","author":"H Watanabe","year":"2025","unstructured":"Watanabe H, Inoue Y, Tsuchiya K, et al. Lethal co-expression intolerance underlies the mutually exclusive expression of ASCL1 and NEUROD1 in SCLC cells. npj Precis Oncol. 2025;9(1):74.","journal-title":"npj Precis Oncol"},{"issue":"8088","key":"16618_CR11","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41586-025-09503-z","volume":"647","author":"AS Ireland","year":"2025","unstructured":"Ireland AS, Xie DA, Hawgood SB, et al. Basal cell of origin resolves neuroendocrine\u2013tuft lineage plasticity in cancer. Nature. 2025;647(8088):257\u201367.","journal-title":"Nature"},{"issue":"1","key":"16618_CR12","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1186\/s12967-025-06724-8","volume":"23","author":"J Qu","year":"2025","unstructured":"Qu J, Sun W, Li Y, et al. Immune profiling identifies CD161\u2009+\u2009CD127+CD8\u2009+\u2009T cells as a predictive biomarker for Anti-PD-L1 therapy response in the SCLC-I subtype. J Transl Med. 2025;23(1):711.","journal-title":"J Transl Med"},{"issue":"1","key":"16618_CR13","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12957-022-02528-y","volume":"20","author":"X-L Ding","year":"2022","unstructured":"Ding X-L, Su Y-G, Yu L, et al. Clinical characteristics and patient outcomes of molecular subtypes of small cell lung cancer (SCLC). World J Surg Oncol. 2022;20(1):54.","journal-title":"World J Surg Oncol"},{"issue":"24","key":"16618_CR14","doi-asserted-by":"publisher","first-page":"9115","DOI":"10.1002\/cam4.4402","volume":"10","author":"Q Xie","year":"2021","unstructured":"Xie Q, Chu H, Yi J, et al. Identification of a prognostic immune-related signature for small cell lung cancer. Cancer Med. 2021;10(24):9115\u201328.","journal-title":"Cancer Med"},{"key":"16618_CR15","doi-asserted-by":"publisher","first-page":"175883592513267","DOI":"10.1177\/17588359251326705","volume":"17","author":"JU Lim","year":"2025","unstructured":"Lim JU, Ryu WK, Park N, et al. Current and future perspectives in extensive-stage small-cell lung cancer. Ther Adv Med Oncol. 2025;17:17588359251326705.","journal-title":"Ther Adv Med Oncol"},{"issue":"23","key":"16618_CR16","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.3390\/diagnostics14232660","volume":"14","author":"A Vigdorovits","year":"2024","unstructured":"Vigdorovits A, Olteanu G-E, Pascalau A-V, et al. Novel Immunohistochemical Profiling of Small-Cell Lung Cancer: Correlations Between Tumor Subtypes and Immune Microenvironment. Diagnostics. 2024;14(23):2660.","journal-title":"Diagnostics"},{"issue":"6","key":"16618_CR17","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1111\/bph.16313","volume":"183","author":"M Attias","year":"2024","unstructured":"Attias M, Piccirillo CA. The impact of Foxp3\u2009+\u2009regulatory T-cells on CD8\u2009+\u2009T\u2010cell dysfunction in tumour microenvironments and responses to immune checkpoint inhibitors. Br J Pharmacol. 2024;183(6):1250\u201370.","journal-title":"Br J Pharmacol"},{"issue":"8","key":"16618_CR18","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.3390\/molecules30081731","volume":"30","author":"D Huang","year":"2025","unstructured":"Huang D, Wang J, Chen L, et al. Molecular Subtypes and Targeted Therapeutic Strategies in Small Cell Lung Cancer: Advances, Challenges, and Future Perspectives. Molecules. 2025;30(8):1731.","journal-title":"Molecules"},{"issue":"3","key":"16618_CR19","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.ccell.2024.01.010","volume":"42","author":"BY Nabet","year":"2024","unstructured":"Nabet BY, Hamidi H, Lee MC, et al. Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade. Cancer Cell. 2024;42(3):429\u2013e434.","journal-title":"Cancer Cell"},{"issue":"1","key":"16618_CR20","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s00432-023-05544-x","volume":"150","author":"L Zhu","year":"2024","unstructured":"Zhu L, Qin J. Predictive biomarkers for immunotherapy response in extensive-stage SCLC. J Cancer Res Clin Oncol. 2024;150(1):22.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"16618_CR21","doi-asserted-by":"publisher","first-page":"4703","DOI":"10.1038\/s41467-023-40398-4","volume":"14","author":"A Castiglioni","year":"2023","unstructured":"Castiglioni A, Yang Y, Williams K, et al. Combined PD-L1\/TGF\u03b2 blockade allows expansion and differentiation of stem cell-like CD8 T cells in immune excluded tumors. Nat Commun. 2023;14(1):4703.","journal-title":"Nat Commun"},{"issue":"1","key":"16618_CR22","doi-asserted-by":"publisher","first-page":"ltad009","DOI":"10.1093\/immadv\/ltad009","volume":"3","author":"AJ Patel","year":"2023","unstructured":"Patel AJ, Middleton GW. TIGIT-based immunotherapeutics in lung cancer. Immunother Adv. 2023;3(1):ltad009.","journal-title":"Immunother Adv"},{"issue":"1","key":"16618_CR23","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13045-025-01690-6","volume":"18","author":"X Zhai","year":"2025","unstructured":"Zhai X, Zhang Z, Chen Y, et al. Current and future therapies for small cell lung carcinoma. J Hematol Oncol. 2025;18(1):37.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"16618_CR24","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.jtho.2019.01.019","volume":"14","author":"X Zhao","year":"2019","unstructured":"Zhao X, Kallakury B, Chahine JJ, et al. Surgical Resection of SCLC: Prognostic Factors and the Tumor Microenvironment. J Thorac Oncol. 2019;14(5):914\u201323.","journal-title":"J Thorac Oncol"},{"issue":"11","key":"16618_CR25","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1007\/s00595-025-03070-6","volume":"55","author":"K Onodera","year":"2025","unstructured":"Onodera K, Notsuda H, Kumata S, et al. PD-L1 expression correlates with the oncological severity and prognosis of early-stage lung cancer. Surg Today. 2025;55(11):1635\u201343.","journal-title":"Surg Today"},{"issue":"1","key":"16618_CR26","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1186\/s13019-024-03166-z","volume":"19","author":"M Tamura","year":"2024","unstructured":"Tamura M, Furukawa N, Sakai T, et al. Prognostic significance of CEA reduction rate in patients with abnormally high preoperative CEA levels who underwent surgery for lung cancer. J Cardiothorac Surg. 2024;19(1):662.","journal-title":"J Cardiothorac Surg"},{"issue":"2","key":"16618_CR27","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1097\/CM9.0000000000002693","volume":"137","author":"H Guo","year":"2023","unstructured":"Guo H, Li W, Guo Y, et al. Molecular classification of small cell lung cancer subtypes: Characteristics, prognostic factors, and clinical translation. Chin Med J. 2023;137(2):130\u20139.","journal-title":"Chin Med J"},{"issue":"23","key":"16618_CR28","doi-asserted-by":"publisher","first-page":"3996","DOI":"10.3390\/cancers16233996","volume":"16","author":"DH Kang","year":"2024","unstructured":"Kang DH, Lee J, Im S, et al. Navigating the Complexity of Resistance in Lung Cancer Therapy: Mechanisms, Organoid Models, and Strategies for Overcoming Treatment Failure. Cancers. 2024;16(23):3996.","journal-title":"Cancers"},{"key":"16618_CR29","doi-asserted-by":"publisher","first-page":"100907","DOI":"10.1016\/j.drup.2022.100907","volume":"66","author":"K Pang","year":"2023","unstructured":"Pang K, Shi Z-D, Wei L-Y, et al. Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1\/PD-L1 blockade. Drug Resist Updates. 2023;66:100907.","journal-title":"Drug Resist Updates"},{"issue":"6","key":"16618_CR30","doi-asserted-by":"publisher","first-page":"701","DOI":"10.3390\/genes15060701","volume":"15","author":"P Trillo Aliaga","year":"2024","unstructured":"Trillo Aliaga P, Del Signore E, Fuorivia V, et al. The Evolving Scenario of ES-SCLC Management: From Biology to New Cancer Therapeutics. Genes. 2024;15(6):701.","journal-title":"Genes"},{"issue":"7","key":"16618_CR31","doi-asserted-by":"publisher","first-page":"100184","DOI":"10.1016\/j.modpat.2023.100184","volume":"36","author":"S Hwang","year":"2023","unstructured":"Hwang S, Hong TH, Kim HK, et al. Whole-Section Landscape Analysis of Molecular Subtypes in Curatively Resected Small Cell Lung Cancer: Clinicopathologic Features and Prognostic Significance. Mod Pathol. 2023;36(7):100184.","journal-title":"Mod Pathol"},{"issue":"3","key":"16618_CR32","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s00262-022-03270-w","volume":"72","author":"D Dora","year":"2023","unstructured":"Dora D, Rivard C, Yu H, et al. Protein Expression of immune checkpoints STING and MHCII in small cell lung cancer. Cancer Immunol immunotherapy: CII. 2023;72(3):561\u201378.","journal-title":"Cancer Immunol immunotherapy: CII"},{"issue":"4","key":"16618_CR33","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/s43018-019-0020-z","volume":"1","author":"CA Stewart","year":"2020","unstructured":"Stewart CA, Gay CM, Xi Y, et al. Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer. Nat Cancer. 2020;1(4):423\u201336.","journal-title":"Nat Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16618-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16618-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16618-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:45:04Z","timestamp":1792626304000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16618-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16618"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16618-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"assertion":[{"value":"14 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol and the use of clinical data were approved by the Biomedical Ethics Review Committee of West China Hospital, Sichuan University (Approval No. 2021.1760). The need for informed consent was waived by the same committee, as this was a retrospective study using only anonymized data. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1264"}}